Please login to the form below

Not currently logged in
Email:
Password:

Transition Therapeutics

This page shows the latest Transition Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

Eli Lilly has licensed rights to an experimental drug that builds muscle to Canada's Transition Therapeutics. ... In a statement, Transition limited itself to saying that the profile of the drug "creates a number of development opportunities.".

Latest news

  • Transition halts diabetes drug development

    Transition halts diabetes drug development. Transition Therapeutics has discontinued development of a new therapy for type 2 diabetes after it failed to meet efficacy endpoints. ... Transition Therapeutics has discontinued development of a potential new

  • Lilly halts Alzheimer's drug development

    Only days ago, Elan announced its own disappointing results for another Alzheimer's drug targeting amyloid plaques that the company is developing with Transition Therapeutics.

  • FDA approves generic Aricept for dementia

    Elan stops Alzheimer's drug trial after deaths. Dublin-based Elan, and its partner Transition Therapeutics, have removed two high doses of their experimental orally-administered Alzheimer's therapy from a

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Transition Therapeutics with the out-licence of the phase II ready selective androgen receptor modulator TT701 to Transition. ... 105.5. Eli Lilly/ Transition Therapeutics. Licence agreement. For TT701 a selective androgen receptor modulator in P2 for

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    143. Lilly / Transition Therapeutics. Licence, collaboration and option‡. TT-601 for osteoarthritis pain (preclinical). ... EU. ‡ Payable to Transition Therapeutics if Lilly exercises its option to re-acquire at clinical proof of concept.

  • Pharma deals during July 2013 Pharma deals during July 2013

    Lilly entered into a deal with Transition Therapeutics with an interesting structure that allows the large pharma to buy back the asset, TT-601 for the treatment of pain in osteoarthritis, ... If Lilly exercises its option to reacquire the rights to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    London, UK-based Orchard Therapeutics has appointed Mark Rothera as its new president and chief executive officer at a time when the group progresses its clinical pipeline. ... Prior to his new role, Rothera served as chief commercial officer at PTC

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics. ... He said: “ The transition to a product-oriented oncology therapeutics company is a pivotal moment in

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics